Form 4: Vaxcyte Insider Trades: President & CFO Buys and Sells Stock

Vaxcyte, Inc. reports insider transactions by President and CFO Andrew Guggenhime, involving the acquisition and disposition of common stock.

Summary

• Andrew Guggenhime, President and CFO of Vaxcyte, Inc., engaged in a transaction on June 18, 2026.
• He acquired 10,000 shares of common stock at a price of $5.35 per share.
• Concurrently, he disposed of 10,000 shares of common stock at a price of $53.00 per share.
• Following these transactions, Guggenhime beneficially owns 104,395 shares directly.
• An additional 61,850 shares are held indirectly through ALG 2025 GRAT HOLDINGS LLC, with the reporting person as the annuitant and trustee of the underlying trust.
• Guggenhime also holds vested stock options for 236,827 shares, with an exercise price of $5.35, expiring May 11, 2030.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to the significant profit-taking by a key executive, despite the acquisition at a lower price and the use of a 10b5-1 plan.

Positives

• Acquisition of 10,000 shares at a lower price ($5.35) suggests a potential belief in future value appreciation.
• The reporting person continues to hold a significant number of shares (104,395 directly and 61,850 indirectly) and vested options (236,827).

Negatives

• A significant disposition of 10,000 shares at a much higher price ($53.00) compared to the acquisition price ($5.35) indicates a realization of profit by an insider.

Risks

• The sale of shares at a significantly higher price than the purchase price could be interpreted as an insider believing the stock has reached a peak or is overvalued at the current trading price.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the acquisition of shares at a lower price could imply a positive outlook by the reporting person.

Management Comments

• The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026.
• Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.
• Option is fully vested and exercisable.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common in the biotechnology sector as executives manage their personal portfolios. The significant price difference between the acquisition and sale in this filing for Vaxcyte (PCVX) warrants attention from investors.

Stakeholder Impact

• Shareholders may interpret the sale at a high price as a signal of potential overvaluation or a lack of immediate upside from the executive's perspective.
• Employees holding stock options may be influenced by the executive's profit-taking strategy.

Next Steps

• Monitor future insider trading activity for Vaxcyte, Inc. to gauge executive sentiment.
• Observe the company's stock performance following this transaction.

Key Dates

Recommendation

The filing indicates a planned sale of stock by a key executive at a significant profit, executed under a 10b5-1 plan. While the acquisition at a lower price could be seen as positive, the substantial sale at a much higher price suggests profit-taking. Without further company-specific news or financial performance data, a 'hold' recommendation is prudent, allowing investors to observe further developments.

Keywords

Vaxcyte, PCVX, Insider Trading, Form 4, Stock Transaction, Andrew Guggenhime, Common Stock, Stock Options, Beneficial Ownership